

JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1
(OVER MICRO-PURCHASE THRESHOLD(\$3.5K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW FAR13.104, COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW FAR13.106-1(b), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW FAR13.106-3(b)(3), COs are required to include additional statements *explaining the absence of competition* (see 13.106-1 for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW FAR13.106-3(b)(3). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

1. ACQUISITION PLAN ACTION ID: 509-17-3-921-0008	1A. PROJECT/TASK No.	1B. ESTIMATED AMOUNT: \$20,098.00
--	-----------------------------	---


2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:
This request is for the procurement of Bard Peripheral Vascular graft (implants) which are used for limb revitalization. These grafts are exact matches to existing sets that are currently being used.

3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:

Arterial Bypass Graft Patency is designed to address the challenge of intimal hyperplasia. Provides higher flow velocity and increases wall shear stress to inhibit neointimal thickening. Carbon-impregnated ePTFE vascular grafts, compared to grafts without carbon, are associated with a decrease in platelet adhesion and fibrin deposition.

4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED: The manufacturer, Bard Peripheral, made known to us that there are no authorized distributor(s) who can meet the needs of the government. The suggested vendor is the sole source for manufacturing and purchase of the needed item. Considering that these must be exact matches to the existing instruments and for continuity of care, the only sources available is the manufacturer to supply the needed instrument and implant sets. As a result, no other sources were sought.

5. Contracting Officer's Certification: *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Note: COs are required to make a determination of price reasonableness IAW FAR 13.106-3. See the Commercial Supply and Service SOP for Price Reasonableness templates.*

Signature: 
Date: 8/25/2015
Name: Sebastian Anderson
Title: Contracting Officer

NCO: _____